|
Clinical utility of comprehensive circulating tumor DNA (ctDNA) testing compared to standard-of-care (SoC) tissue testing in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts). |
|
|
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Sysmex; Sysmex; Sysmex; Sysmex |
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Celgene; Celgene; Celgene; Celgene |
|
|
Honoraria - Bayer; Bayer; Bayer; Bayer |
|
|
Consulting or Advisory Role - Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Novartis Pharmaceuticals UK Ltd.; Novartis Pharmaceuticals UK Ltd.; Novartis Pharmaceuticals UK Ltd.; Novartis Pharmaceuticals UK Ltd.; Pfizer; Pfizer; Pfizer; Pfizer |
Travel, Accommodations, Expenses - Ipsen; Ipsen; Ipsen; Ipsen |
|
|
No Relationships to Disclose |
|
|
Employment - VISUfarma (I); VISUfarma (I); VISUfarma (I); VISUfarma (I) |
Stock and Other Ownership Interests - VISUfarma (I); VISUfarma (I); VISUfarma (I); VISUfarma (I) |
Consulting or Advisory Role - Merck; Merck; Merck; Merck |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche; Roche; Roche; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Kirin Pharmaceuticals; Kirin Pharmaceuticals; Kirin Pharmaceuticals; Kirin Pharmaceuticals |
Travel, Accommodations, Expenses - Roche; Roche; Roche; Roche |
|
|
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen |
|
|
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health; Guardant Health; Guardant Health; Guardant Health; Veracyte; Veracyte; Veracyte; Veracyte |
Leadership - Biolase; Biolase; Biolase; Biolase; Guardant Health; Guardant Health; Guardant Health; Guardant Health |
Stock and Other Ownership Interests - Biolase; Biolase; Biolase; Biolase; Forward; Forward; Forward; Forward; Guardant Health; Guardant Health; Guardant Health; Guardant Health |
Consulting or Advisory Role - Forward; Forward; Forward; Forward |
Research Funding - Guardant Health; Guardant Health; Guardant Health; Guardant Health |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health; Guardant Health; Guardant Health; Guardant Health |
Stock and Other Ownership Interests - Guardant Health; Guardant Health; Guardant Health; Guardant Health |
|
|
Employment - Guardant Health; Guardant Health; Guardant Health; Guardant Health |
Leadership - CureSeq; CureSeq; CureSeq; CureSeq |
Stock and Other Ownership Interests - Guardant Health; Guardant Health; Guardant Health; Guardant Health |
Consulting or Advisory Role - CureSeq; CureSeq; CureSeq; CureSeq; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma |
Patents, Royalties, Other Intellectual Property - University of California, San Francisco; University of California, San Francisco; University of California, San Francisco; University of California, San Francisco |
|
|
Consulting or Advisory Role - Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche |
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme |